Michael Wolff was at the "edge of a cliff" when he was diagnosed with a cancer that affects less than 300 patients a year in the U.S.

A report's revelation that some popular brands contain cancer-causing chemicals has confirmed suspicions about oversights in the beauty industry, but how dangerous are they?

Waksal, who is not a medical doctor, imported the veterinary drug along with other “unapproved ingredients” from Colombia.

The technology is genuinely useful for scientific discovery, but its applications are less dramatic than you might think.

Akeso Inc. scored U.S. FDA approval of the PD-1 monoclonal antibody penpulimab in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

Penpulimab is approved for multiple indications in China, but this marks the first US approval for the novel monoclonal ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

The leadership shown by HHS in addressing this problem with clear guidelines and expectations provides much-needed clarity to ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

The FDA has approved Akeso Inc.’s penpulimab-kcqx in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic NPC.

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...